Therefore, downregulating PDK4 can effectively promote the expression of CD20 and enhance the effect of rituximab, offering new strategies and methods for the clinical treatment of DLBCL patients with negative or low expression of CD20. The gene discussed is PDK4; the disease is diffuse large B-cell lymphoma.